concept

LOX/LOXL1-4

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about LOX/LOXL1-4: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

75Connections

1Hypotheses

1Analyses

47Outgoing

28Incoming

No summary available yet. View on Wiki →

💡 Concept Info

Name	LOX/LOXL1-4
Key Genes/Proteins	LOXL1-4, LOX, Vegfr, Laminin
Related Diseases	Tumor, Cancer, ALS, Ms, Als

Wiki Pages (20)

Knowledge base pages for this entity

Pathway Diagram

graph TD
    LOX_LOXL1_4["LOX/LOXL1-4"]
    LOX_LOXL1_4 -->|"expressed in"| Tumor["Tumor"]
    LOX_LOXL1_4 -->|"regulates"| Cancer["Cancer"]
    LOX_LOXL1_4 -->|"regulates"| ALS["ALS"]
    LOX_LOXL1_4 -->|"target for"| Ms["Ms"]
    LOX_LOXL1_4 -->|"implicated in"| Als["Als"]
    LOX_LOXL1_4 -->|"regulates"| CANCER["CANCER"]
    LOX["LOX"] -->|"regulates"| LOX_LOXL1_4
    GENES["GENES"] -->|"expressed in"| LOX_LOXL1_4
    LOXL1_4["LOXL1-4"] -->|"stabilizes"| LOX_LOXL1_4
    CANCER -->|"regulates"| LOX_LOXL1_4
    LOXL3["LOXL3"] -->|"target for"| LOX_LOXL1_4
    LOXL1["LOXL1"] -->|"regulates"| LOX_LOXL1_4

Outgoing (47)

Target	Relation	Type	Str
Tumor	expressed_in	disease	0.65
Cancer	regulates	disease	0.65
ALS	regulates	disease	0.65
Ms	therapeutic_target	disease	0.65
Tumor	therapeutic_target	disease	0.65
Als	implicated_in	disease	0.65
Als	regulates	disease	0.65
LOXL1-4	regulates	gene	0.60
LOX	regulates	gene	0.60
LOX	stabilizes	gene	0.60
LOXL1-4	associated_with	entity	0.60
LOX	associated_with	gene	0.60
LOXL1-4	stabilizes	gene	0.60
Vegfr	therapeutic_target	protein	0.60
Laminin	therapeutic_target	protein	0.60
Vegf	therapeutic_target	protein	0.60
CANCER	regulates	gene	0.60
Lipid Metabolism	regulates	pathway	0.60
Immune Response	regulates	pathway	0.60
LOXL2	therapeutic_target	gene	0.60
Lipid Metabolism	implicated_in	pathway	0.60
Immune Response	implicated_in	pathway	0.60
LOXL3	expressed_in	gene	0.60
LOXL1	regulates	gene	0.60
LOXL3	stabilizes	gene	0.60
LR.LOXL3	regulates	gene	0.60
LOXL1	stabilizes	gene	0.60
RNA	therapeutic_target	gene	0.60
LOXL3	therapeutic_target	gene	0.60
Macrophage	therapeutic_target	cell_type	0.60
Epithelial	therapeutic_target	cell_type	0.60
T Cell	therapeutic_target	cell_type	0.60
LOXL3	associated_with	gene	0.60
LOXL2	expressed_in	gene	0.60
RNA	expressed_in	gene	0.60
AND	regulates	gene	0.60
GENES	expressed_in	gene	0.60
Egfr	therapeutic_target	protein	0.60
Collagen	therapeutic_target	protein	0.60
App	therapeutic_target	protein	0.60
Macrophage	expressed_in	cell_type	0.55
T Cell	expressed_in	cell_type	0.55
neurodegeneration	associated_with	disease	0.50
PDGFRB	debate_co_mention	gene	0.45
SDC1	debate_co_mention	gene	0.45
SDC1	co_associated_with	gene	0.40
PDGFRB	co_associated_with	gene	0.40

Incoming (28)

Source	Relation	Type	Str
LOX	regulates	gene	0.60
LOX	stabilizes	gene	0.60
LOXL1-4	stabilizes	gene	0.60
LOX	associated_with	gene	0.60
LOXL1-4	regulates	gene	0.60
GENES	expressed_in	gene	0.60
CANCER	regulates	entity	0.60
GENES	therapeutic_target	gene	0.60
LOXL3	therapeutic_target	gene	0.60
LOXL1	regulates	gene	0.60
AND	regulates	gene	0.60
LOXL3	associated_with	gene	0.60
LOXL1	associated_with	gene	0.60
LR.LOXL3	implicated_in	gene	0.60
AND	implicated_in	gene	0.60
LOXL2	expressed_in	gene	0.60
RNA	expressed_in	gene	0.60
LOXL1	stabilizes	gene	0.60
RNA	therapeutic_target	gene	0.60
GJA1	debate_co_mention	gene	0.45
HCRTR1/HCRTR2	debate_co_mention	gene	0.45
KCNK2	debate_co_mention	gene	0.45
LOX	debate_co_mention	gene	0.45
HCRTR1	debate_co_mention	gene	0.45
AQP1	co_associated_with	gene	0.40
GJA1	co_associated_with	gene	0.40
HCRTR1/HCRTR2	co_associated_with	gene	0.40
KCNK2	co_associated_with	gene	0.40

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In	0.515	neurodegeneration	Perivascular spaces and glymphatic clear

Mentioning Analyses (1)

Scientific analyses that reference this entity

Perivascular spaces and glymphatic clearance failure in AD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.623

Related Papers (17)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Evolutionary conservation and Immunoregulatory function of LOXL3 gene in lamprey [PMID:40816690]	Pang Y, Yan Z, Gao Y, Li D, Zhao L, Ma G	Fish Shellfish Immunol	2025	1
Machine learning-based in-silico analysis identifies signatures of lysyl oxidase [PMID:40186284]	Xu Q, Ma L, Streuer A, Altrock E, Schmit	Cell Commun Signal	2025	1
Arteriolar degeneration and stiffness in cerebral amyloid angiopathy are linked [PMID:40465757]	["Ventura-Antunes L", "Nackenoff A", "Ro	Alzheimer's & dementia : the j	2025	0
LOX-mediated ECM mechanical stress induces Piezo1 activation in hypoxic-ischemic [PMID:39260063]	["Jiang D", "Zhao J", "Zheng J", "Zhao Y	Redox biology	2024	0
Cardiomyocyte senescence and the potential therapeutic role of senolytics in the [PMID:39119147]	["Zhai P", "Sadoshima J"]	The journal of cardiovascular	2024	0
Effects of Age, Sex, and Extracellular Matrix Integrity on Aortic Dilatation and [PMID:37470181]	["Weiss D", "Rego B", "Cavinato C", "Li	Arteriosclerosis, thrombosis,	2023	0
Single-cell analysis reveals lysyl oxidase (Lox) [PMID:36706988]	["Li H", "Zhu X", "Cao X", "Lu Y", "Zhou	Journal of advanced research	2023	0
Mesenchymal stem cell-derived exosomal miR-27b-3p alleviates liver fibrosis via [PMID:37328872]	["Cheng F", "Yang F", "Wang Y", "Zhou J"	Journal of nanobiotechnology	2023	0
Influence of Substrate Stiffness on Barrier Function in an iPSC-Derived [PMID:35096185]	["Bosworth A", "Kim H", "O'Grady K", "Ri	Cellular and molecular bioengi	2022	0
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activat [PMID:35526014]	Sudwarts A, Ramesha S, Gao T	Mol Neurodegener	2022	0
Correlation of Matrisome-Associatted Gene Expressions with LOX Family Members in [PMID:36076905]	["Laurentino T", "Soares R", "Marie S",	International journal of molec	2022	0
Effect of lysyl oxidase (LOX) on corpus cavernous fibrosis caused by ischaemic p [PMID:29278308]	["Gao L", "Wu C", "Fu F", "You X", "Ma X	Journal of cellular and molecu	2018	0
Targeting lysyl oxidase reduces peritoneal fibrosis. [PMID:28800626]	["Harlow C", "Wu X", "van Deemter M", "G	PloS one	2017	0
LOX-1 and neurodegeneration. [PMID:24929221]	Liu J	Neurosci Lett	2014	0
Gene-environment interaction models to unmask susceptibility mechanisms in Parki [PMID:24430802]	["Chou V", "Ko N", "Holman T", "Manning-	Journal of visualized experime	2014	0
Developmental vasculotoxicity associated with inhibition of semicarbazide-sensit [PMID:10079209]	["Langford S", "Trent M", "Balakumaran A	Toxicology and applied pharmac	1999	0
Spontaneous rupture of the internal elastic lamina in the rat: the manifestation [PMID:2575918]	["Capdeville M", "Coutard M", "Osborne-P	Blood vessels	1989	0

LOX/LOXL1-4

Understanding Entity Pages

Wiki Pages (20)

cbs-psp-daily-action-plan

Section 148: Advanced Nutritional Biochemistry in CBS/PSP

Sulforaphane and Nrf2 Activation for Neuroprotection

DNA Damage Response in Corticobasal Syndrome

ASC (PYCARD)

RAN Gene

Targeted Protein Degradation (PROTACs)

Tau-Targeted Therapeutics

Therapeutic Antibody Comparison Matrix

NRF2 Gene

nadph-oxidase-inhibitors

Tau Aggregation Inhibitors

NRF2 — Nuclear Factor Erythroid 2-Related Factor 2

Prostaglandin and Eicosanoid Signaling in CBS/PSP

Kinase and Phosphatase Therapeutic Target Matrix

Section 193 Advanced Integrated Cell Stress Response Therapy in CBS/PSP

ACE Protein

nrf2-activators-parkinsons-disease

Phagocytosis Modulation Therapy